Two pharmaceutical companies have embarked on a brave new world, having begun human testing for the first time on a drug treatment for obsessive-compulsive disorder designed by artificial intelligence. British startup Exscientia and Japan's Sumitomo Dainippon Pharma used artificial intelligence to create the drug in less than 12 months, cutting four years from the average time it takes ordinary humans to develop a medication. Exscientia CEO Andrew Hopkins described the clinical human trial of the drug -- a molecule called DSP-1181 -- as a "key milestone in drug discovery." TOP STORIES Milwaukee teacher placed on leave after praising Rush Limbaugh's cancer diagnosis Impeachment 2.0? "Our driving motivation is to accelerate the range of innovative drugs from cutting-edge science entering into the clinic to increase the treatment options for patients. That means reducing the time to make and test a drug. The consumer should see benefits from faster progress to the clinic," Mr. Hopkins told The Washington Times.

At DeepMind, we've built a unique culture and work environment where long-term ambitious research can flourish. Our interdisciplinary Science team applies the best of our artificial intelligence research to challenges within the natural sciences. The Science team has already made a number of high profile breakthroughs, and we have all the ingredients in place to make further significant progress over the coming years. To succeed in this role you will need to be passionate about advancing science using machine learning and other computational techniques. You'll join a spectrum of domain experts, ML research scientists, and engineers exploring a diverse set of important scientific problems in biology, physics, mathematics, and other areas.

Sir Winston Churchill's birthplace, Blenheim Palace, is experimenting with a five-foot tall robot tour guide, called Betty. The autonomous robot is the latest in a series of tech advances in the grand stately home. Betty is designed to seek out visitors to provide information and answer their questions. It even takes selfies with visitors and can upload them to social media using the Twitter hashtag #bettyinthepalace. New addition: Blenheim Palace's new robotic tour guide wanders the halls of the stately home.

The scientist had gone too far in his invention, "mocking" God's power by recreating life: Man as God. Shelly seems to be self-healing here, trying to let go of her daughter's loss, abandoning the hope of some science-based resuscitation. Death must be accepted as final; the creature is not truly human but a phantasm, hovering between human and god-like, all-powerful and profoundly lonely. Fast-forward 200 years, and the cutting-edge science of our time is now a combination of electricity, digital technology, and genetics. Much has changed since Galvani and Volta -- but not the hope of so many to use science to go beyond death, acquiring some sort of immortality by transcending the weakness of the flesh. Transhumanists firmly believe that science will be able to do this, and fairly soon. Possibly, through genetic manipulation and the cloning of oneself, or through a "brain dump," the transfer of your very own neuronal code into machines capable of storing it and of reigniting the synaptic connections so that you can become "pure spirit" so to speak, a digital disembodied creature, transferable from machine to machine like a piece of software: a modern version of the Resurrection.